Abcam logo

ABCM - Abcam Share Price

$22.46 0.2  0.8%

Last Trade - 9:00pm

Large Cap
Market Cap £3.64bn
Enterprise Value £3.53bn
Revenue £297.7m
Position in Universe 1475th / 7242
Unlock ABCM Revenue
Relative Strength (%)
1m +5.10%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.76%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2016 2017 2018 2019 2020 2021 2022E 2023E CAGR / Avg
171.7 217.1 233.2 259.9 260 297.7 354.3 398.5 +11.6%
+10.0 +7.4 +84.8 -15.4 -31.5 -46.3 +83.8 +30.4
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2021, Abcam Plcrevenues increased 15% to £297.7M. Net income increased 30%to £16.2M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Net income benefited from Impairment ofintangible assets decrease from £14.9M (expense) to £0K,Acquisition costs decrease of 76% to £1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ABCM Revenue Unlock ABCM Revenue

Net Income

ABCM Net Income Unlock ABCM Revenue

Normalised EPS

ABCM Normalised EPS Unlock ABCM Revenue

PE Ratio Range

ABCM PE Ratio Range Unlock ABCM Revenue

Dividend Yield Range

ABCM Dividend Yield Range Unlock ABCM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ABCM EPS Forecasts Unlock ABCM Revenue
Profile Summary

Abcam plc is a global life sciences company. The Company is focused on identifying, developing and distributing reagents and tools which are required in the fields of life science research. The Company's product offering includes portfolio of antibodies and related protein research tools that are fundamental to its customers' research and experimental workflow. The Company's product type includes primary antibodies, secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selector, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers. The Company's products are used by researchers to study biological pathways, which is critical for scientific research, diagnostics and drug discovery. The Company serves scientists and researchers in academic institutions, research institutes and pharmaceutical, biotechnology and diagnostics companies.

Last Annual June 30th, 2021
Last Interim June 30th, 2021
Incorporated February 12, 1998
Public Since November 3, 2005
No. of Shareholders: n/a
No. of Employees: 1,500
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market (Dual Listing)
Shares in Issue 226,781,415
Free Float (0.0%)
Eligible for
ABCM Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ABCM
Upcoming Events for ABCM
Frequently Asked Questions for Abcam
What is the Abcam share price?

As of 9:00pm, shares in Abcam are trading at $22.46, giving the company a market capitalisation of £3.64bn. This share price information is delayed by 15 minutes.

How has the Abcam share price performed this year?

Shares in Abcam are currently trading at $22.46 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abcam price has moved by % over the past year.

What are the analyst and broker recommendations for Abcam?

Of the analysts with advisory recommendations for Abcam, there are there are currently 0 "buy" , 6 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Abcam is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Abcam next release its financial results?

Abcam is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Abcam dividend yield?

Abcam does not currently pay a dividend.

Does Abcam pay a dividend?

Abcam does not currently pay a dividend.

When does Abcam next pay dividends?

Abcam does not currently pay a dividend.

How do I buy Abcam shares?

To buy shares in Abcam you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Abcam?

Shares in Abcam are currently trading at $22.46, giving the company a market capitalisation of £3.64bn.

Where are Abcam shares listed? Where are Abcam shares listed?

Here are the trading details for Abcam:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ABCM
What kind of share is Abcam?

Based on an overall assessment of its quality, value and momentum, Abcam is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Abcam share price forecast 2021?

Shares in Abcam are currently priced at $22.46. At that level they are trading at 10.35% premium to the analyst consensus target price of 0.00.

Analysts covering Abcam currently have a consensus Earnings Per Share (EPS) forecast of 0.23403 for the next financial year.

How can I tell whether the Abcam share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abcam. Over the past six months, the relative strength of its shares against the market has been 1.86%. At the current price of $22.46, shares in Abcam are trading at 8.08% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Abcam PE Ratio?

The Abcam PE ratio based on its reported earnings over the past 12 months is 0.127k. The shares are currently trading at $22.46.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Abcam?

Abcam's management team is headed by:

Alan Hirzel - CEO
Mara Aspinall - NID
Giles Kerr - NID
Marc Perkins - GCN
Michael Baldock - CFO
Chienling Lee - NED
Mark Capone - NED
Sally Crawford - NED
Who are the major shareholders of Abcam?

Here are the top five shareholders of Abcam based on the size of their shareholding:

Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 3.91% (8.87m shares)
Vanguard Health Care Fund Mutual Fund
Percentage owned: 2.59% (5.88m shares)
Champlain Investment Partners, LLC Investment Advisor
Percentage owned: 1.08% (2.44m shares)
Brown Advisory Investment Advisor/Hedge Fund
Percentage owned: 0.76% (1.72m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 0.55% (1.25m shares)
Similar to ABCM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.